Recro Pharma (NASDAQ:REPH) Earnings Information
Recro Pharma last released its earnings results on November 8th, 2019. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $25.26 million for the quarter, compared to analysts' expectations of $19.83 million. Recro Pharma has generated ($2.49) earnings per share over the last year. Recro Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2020 based off prior year's report dates.
Recro Pharma Earnings Estimates and Actuals by Quarter
The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.
Recro Pharma (NASDAQ:REPH) Earnings Estimates
2019 EPS Consensus Estimate: ($0.81)
2020 EPS Consensus Estimate: $0.66
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2019 | 2 | ($0.88) | ($0.61) | ($0.75) |
| Q2 2019 | 2 | ($0.33) | ($0.04) | ($0.19) |
| Q3 2019 | 2 | ($0.06) | $0.13 | $0.04 |
| Q4 2019 | 2 | $0.07 | $0.11 | $0.09 |
| Q1 2020 | 1 | $0.24 | $0.24 | $0.24 |
| Q2 2020 | 1 | $0.17 | $0.17 | $0.17 |
| Q3 2020 | 1 | $0.13 | $0.13 | $0.13 |
| Q4 2020 | 1 | $0.12 | $0.12 | $0.12 |
| Q1 2021 | 1 | $0.22 | $0.22 | $0.22 |
| Q2 2021 | 1 | $0.37 | $0.37 | $0.37 |
| Q3 2021 | 1 | $0.24 | $0.24 | $0.24 |
Recro Pharma (NASDAQ REPH) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | GAAP EPS | Revenue Estimate | Actual Revenue | Conference Call | Details |
|---|
2/18/2020
(Estimated) | | | | | | | | |
| 11/8/2019 | Q3 | ($0.13) | ($0.19) | ($0.19) | $19.83 million | $25.26 million | Listen | |
| 8/8/2019 | Q2 2019 | ($0.42) | ($0.13) | ($0.13) | $24.06 million | $31.26 million | N/A | |
| 5/10/2019 | 3/31/2019 | ($0.79) | ($0.10) | ($0.10) | $20.51 million | $25.07 million | Transcript | |
| 2/19/2019 | Q4 2018 | ($0.7460) | ($0.58) | $0.76 | $16.01 million | $17.78 million | N/A | |
| 11/7/2018 | 9/30/2018 | ($0.67) | ($0.64) | ($0.64) | $16.77 million | $18.28 million | N/A | |
| 8/7/2018 | Q2 2018 | ($1.34) | ($0.62) | ($0.62) | $16.81 million | $21.74 million | N/A | |
| 5/9/2018 | Q1 2018 | ($0.68) | ($0.65) | ($0.65) | $17.32 million | $19.54 million | N/A | |
| 2/27/2018 | Q4 2017 | ($0.85) | ($0.63) | $0.01 | $12.88 million | $19.04 million | N/A | |
| 11/9/2017 | Q3 2017 | ($0.75) | ($0.48) | ($0.48) | $13.93 million | $17.11 million | N/A | |
| 8/10/2017 | Q2 2017 | ($0.54) | ($0.48) | ($0.48) | $14.90 million | $16.93 million | N/A | |
| 5/11/2017 | Q1 2017 | ($0.5750) | ($0.42) | ($0.42) | $15.58 million | $18.74 million | N/A | |
| 3/6/2017 | Q4 2016 | ($0.96) | ($0.81) | ($0.81) | $13.25 million | $17.36 million | N/A | |
| 11/10/2016 | Q3 2016 | ($0.71) | ($0.50) | ($0.50) | $13.50 million | $16.95 million | N/A | |
| 8/11/2016 | Q2 2016 | ($0.61) | ($0.83) | ($0.83) | $18.70 million | $17.30 million | N/A | |
| 5/12/2016 | Q1 2016 | ($0.36) | ($0.49) | ($0.27) | $13.00 million | $17.70 million | N/A | |
| 3/24/2016 | Q4 2015 | ($0.37) | ($0.35) | ($1.83) | $13.00 million | $16.75 million | N/A | |
| 11/13/2015 | Q3 2015 | | ($0.24) | ($0.24) | | $16.54 million | N/A | |
| 8/14/2015 | Q2 2015 | | ($0.17) | ($0.17) | | $18.66 million | N/A | |
| 5/12/2015 | Q1 2015 | | ($0.53) | ($0.53) | | | N/A | |
| 3/25/2015 | Q4 2014 | | ($0.45) | ($0.45) | | | N/A | |
| 11/10/2014 | Q3 2014 | | ($0.61) | ($0.61) | | | N/A | |
| 8/12/2014 | Q2 2014 | | ($0.36) | ($0.36) | | | N/A | |
| 5/12/2014 | Q1 2014 | | ($0.20) | ($0.20) | | | Transcript | |
(Earnings results data provided by Zacks Investment Research)
